NAD+ Clinical Use (Off-Label)

What It Is

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a ubiquitous coenzyme required for hundreds of enzyme reactions across all living cells. It is the electron acceptor in mitochondrial oxidative phosphorylation and the substrate for a family of NAD+-consuming enzymes — sirtuins (SIRT1–7), poly-ADP-ribose polymerases (PARPs), and CD38/CD157 — that control DNA repair, chromatin remodeling, circadian rhythm, and energy metabolism. Unlike most compounds in the Kalios database, NAD+ is not a drug or a peptide; it is an endogenous biochemical essential to life. The "anti-aging" interest in NAD+ comes from the consistent observation that intracellular NAD+ concentrations decline substantially with age — in humans, roughly 50% between ages 20 and 60 — and that the decline tracks with dysfunction of the NAD+-consuming enzyme families.

The modern NAD+ era began with the work of David Sinclair (Harvard), Shin-ichiro Imai (Washington University), Charles Brenner (City of Hope), and their collaborators in the 2000s–2010s establishing that (a) sirtuins are NAD+-dependent deacetylases regulating aging-associated pathways, (b) NAD+ falls during aging, (c) administering NAD+ precursors in mice restores youthful NAD+ levels and reverses several aging phenotypes (muscle, metabolic, neurological), and (d) intermediate supply of precursor is rate-limiting rather than nicotinamide availability per se. This framework made NAD+ one of the most commercially active targets in the longevity space.

Clinically, "NAD+ therapy" in the wellness and anti-aging context usually refers to one of three modalities: (1) direct intravenous NAD+ infusion (typically 250–1,000 mg over 4–8 hours), (2) oral NAD+ precursors — nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) — taken daily, or (3) subcutaneous or nasal NAD+ formulations from compounding pharmacies. Of these, oral NR and NMN have the deepest human RCT evidence base (multiple randomized placebo-controlled trials with NAD+ biomarker elevation and some functional endpoints). IV NAD+ has a pilot pharmacokinetic study and a substantial experiential-evidence base in addiction medicine and anti-aging clinics but remains outside FDA-approved use. Oral niacin (nicotinic acid) and nicotinamide (NAM) are approved vitamins and also raise NAD+, though with different downstream profiles.

In the Kalios context, NAD+ sits in an unusual position — it is the most researched target in the longevity ecosystem but also the most contested, because several prominent preclinical findings have failed to replicate cleanly in human RCTs, and because commercial marketing has frequently run ahead of evidence. This profile stays honest about what is and is not established.

Mechanism of Action

NAD+ is mechanistically one of the most consequential molecules in metabolism. It acts both as a redox cofactor (electron carrier) and as a substrate for enzymes that enzymatically consume it.

• Redox coenzyme (NAD+/NADH) — NAD+ accepts electrons during glycolysis, the TCA cycle, and fatty acid oxidation, becoming NADH. NADH then donates electrons to the mitochondrial electron transport chain to generate ATP. Without NAD+, ATP generation halts.
• Sirtuin cofactor (SIRT1–7) — Sirtuins are NAD+-dependent deacetylases that regulate gene expression, metabolic homeostasis, mitochondrial biogenesis (SIRT1/PGC-1α axis), and DNA repair. SIRT1, SIRT6, SIRT7 operate in the nucleus; SIRT2 is cytoplasmic; SIRT3, SIRT4, SIRT5 are mitochondrial. Age-related NAD+ decline reduces sirtuin activity across these compartments.
• PARP substrate (DNA repair) — PARP1 is activated by DNA damage and consumes large amounts of NAD+ to ADP-ribosylate DNA repair proteins. Chronic genomic stress leads to persistent PARP activation and NAD+ drain — a mechanism for accelerated NAD+ depletion in aging and in oxidative-damage states.
• CD38 consumption — CD38 is a cell-surface NAD+-glycohydrolase whose activity increases with age and inflammation. CD38 has emerged as the single largest sink for NAD+ in aged tissue; CD38 inhibition is an active therapeutic target (Camacho-Pereira 2016, PMID 27304511).
• Salvage pathway + NAMPT rate limitation — Most cellular NAD+ is regenerated from nicotinamide (NAM) via nicotinamide phosphoribosyltransferase (NAMPT). NAMPT expression declines with age, contributing to the age-related NAD+ fall. NMN bypasses NAMPT; NR uses the NRK-mediated pathway; NAM/niacin enter upstream.
• Circadian rhythm regulation — NAD+ levels oscillate on a circadian period, feeding back via SIRT1 onto the CLOCK/BMAL1 core clock. NAD+ disruption contributes to circadian dysregulation in aging.
• Mitochondrial biogenesis — SIRT3 activates the mitochondrial unfolded protein response and oxidative metabolism; SIRT1 via PGC-1α increases mitochondrial number. Restoring NAD+ in aged tissue improves mitochondrial function in rodent models (Gomes 2013; Mouchiroud 2013).
• Vascular function — NR supplementation reduced systolic blood pressure and arterial stiffness in the Martens 2018 RCT in middle-aged adults (PMID 29599478), indicating a real vascular effect beyond raw biomarker changes.
• Muscle insulin sensitivity (NMN) — In postmenopausal women with prediabetes, NMN 250 mg/day for 10 weeks improved insulin-stimulated glucose uptake in skeletal muscle (Yoshino 2021, PMID 33888596).
• IV pharmacokinetics — Grant 2019 (PMID 31572171) documented that a 6-hour IV NAD+ infusion in 11 men raised plasma NAD+ levels during infusion with rapid normalization afterward, alongside shifts in bilirubin, GGT, AST, and LD. Only published PK study of direct IV NAD+ in humans.

What the Research Shows

NAD+ is one of the most heavily researched molecules in biology. The following focuses on studies with direct relevance to human administration.

• Mechanistic reviews (Verdin 2015 PMID 26785480; Imai & Guarente 2014 PMID 24786309; Fang 2017) — Definitive consensus reviews establishing NAD+ decline as a central feature of aging and positioning NAD+ restoration as a therapeutic target.
• Sinclair aging mechanism (Gomes et al., Cell 2013; PMID 24360282) — Age-related NAD+ decline produces a pseudohypoxic state in aged mouse tissue; NMN administration reversed multiple mitochondrial dysfunction markers.
• Mitochondrial UPR (Mouchiroud et al., Cell 2013; PMID 23870130) — NAD+/SIRT1 axis activates the mitochondrial unfolded protein response, extending lifespan in C. elegans.
• NR safety + NAD+ elevation (Airhart et al., PLoS One 2017; PMID 29211728) — 8 healthy adults given NR 250–2,000 mg/day for 8 days. Whole blood NAD+ doubled on average; no clinically significant lab safety changes.
• NR chronic + vascular (Martens et al., Nat Commun 2018; PMID 29599478) — 24 middle-aged adults, 1,000 mg NR/day for 6 weeks, crossover RCT. NAD+ elevated; systolic BP lowered ~9 mmHg in stage-1 hypertensive subgroup; arterial stiffness improved. One of the cleanest human NR RCTs.
• NMN in prediabetic women (Yoshino et al., Science 2021; PMID 33888596) — 250 mg NMN/day for 10 weeks; improved skeletal-muscle insulin sensitivity. First major Science publication for NMN in humans. Notably, bulk NAD+ in muscle was not detectably changed; the functional effect may be pathway- and tissue-specific.
• NR in older adults with mild cognitive impairment (Vreones et al., 2023; PMID 37994989) — 1 g NR daily vs placebo for 10 weeks in older adults with MCI. NAD+ elevation confirmed; trends toward cognitive and blood-biomarker benefit; small study.
• IV NAD+ pharmacokinetics (Grant et al., Front Aging Neurosci 2019; PMID 31572171) — 6-hr infusion in 11 healthy men; plasma NAD+ peaks during infusion, normalizes after. Also documented modest shifts in bilirubin, GGT, AST, LD at 8 hours post-infusion.
• NR in skeletal muscle (Elhassan et al., Cell Rep 2019; PMID 31390667) — NR 1 g/day for 21 days in older men elevated muscle NAD+ and produced transcriptomic anti-inflammatory signatures without meaningful strength or performance change in a short window.
• NMN arterial stiffness RCT (Katayoshi 2023, Sci Rep) — Long-term NMN randomized placebo-controlled trial showing favorable arterial-stiffness signal.
• NMN older men muscle (Igarashi 2021) — Japanese older men RCT showing NMN tolerability and preliminary functional signals in muscle.
• Dollerup NR in obesity (Dollerup 2018, Am J Clin Nutr; PMID 30084900) — 12-week NR RCT in obese men; no change in insulin sensitivity despite NAD+ elevation.
• NAM for non-melanoma skin cancer (Chen et al., ONTRAC, N Engl J Med 2015; PMID 26488693) — Phase 3 RCT of 500 mg nicotinamide BID in patients with high-risk NMSC; 23% reduction in new NMSC at 12 months.
• NAD+ and cancer caution (Palmer 2021) — NAD+-boosting strategies have theoretical pro-cancer signal via SIRT-mediated cell survival and NAD+-dependent mitochondrial function in transformed cells. Relevant for the risk-benefit calculation in users with cancer history.
• Systematic reviews (Freeberg 2022; multiple 2023–2025) — Growing systematic-review literature suggests NR and NMN robustly raise blood NAD+ with modest functional-effect signals (vascular, muscle, sleep), but effects are small compared to preclinical promise.

Human Data

Human evidence is strongest for oral precursors (NR, NMN); IV NAD+ is supported by pilot PK and accumulated clinical practice rather than RCT-level data.

• NR RCTs — Airhart 2017 (PMID 29211728), Martens 2018 (PMID 29599478), Elhassan 2019 (PMID 31390667), Dollerup 2018 (PMID 30084900). Consistent NAD+ elevation; small functional effects.
• NMN RCTs — Yoshino 2021 Science (PMID 33888596), Katayoshi 2023 Sci Rep arterial stiffness, Igarashi 2021 Japanese older men. Tolerability established; muscle insulin-sensitivity signal in one pivotal study.
• IV NAD+ pilot (Grant 2019, PMID 31572171) — 11 healthy men, 6-hr infusion. Only published PK study.
• IV NAD+ real-world retrospective — Growing retrospective tolerability data from clinics offering NAD+ infusion; no Phase 3 trial.
• Long-COVID and post-viral fatigue pilots — Preliminary case series and registry data suggest NAD+ restoration may benefit post-viral fatigue syndromes; underpowered.
• Addiction medicine (historical) — NAD+ infusion protocols have been used since the 1960s in some addiction medicine clinics. Evidence is experiential; no modern Phase 3 trial.
• Mild cognitive impairment (Vreones 2023, PMID 37994989) — Small RCT showing NR raises NAD+ and trends toward cognitive benefit.
• Parkinson's (NADPARK, Brakedal 2022, Cell Metab; PMID 35537443) — Phase 1 NR RCT in early Parkinson's disease; increased brain NAD+ levels and trend toward clinical and biomarker benefit.
• ONTRAC NAM chemoprevention (Chen 2015, PMID 26488693) — Phase 3 RCT of oral nicotinamide for NMSC chemoprevention in high-risk patients.

Dosing from the Literature

Dosing varies enormously by modality. Oral precursors (NR, NMN) have labeled supplement ranges; IV and SubQ NAD+ are administered in compounding-pharmacy or concierge-clinic contexts.

Reconstitution & Storage

NAD+ itself is supplied for IV/SubQ use as a sterile solution (commonly 100 mg/mL, 5 mL vials) or as lyophilized powder for reconstitution. Oral precursors (NR, NMN) are supplied as capsules or powder — no reconstitution required.

• IV infusion rate — Too fast → severe infusion symptoms (chest tightness, GI cramping, flushing). Typical safe rate is 1–2 mg/min; slower for first infusion.
• Storage (IV NAD+) — Refrigerate 2–8°C. Pre-mixed compounding solutions have limited stability — check with the compounding pharmacy for BUD (beyond-use date).
• Storage (oral NR / NMN) — Cool, dry place. NMN has been reported less stable than NR at ambient temperature; refrigeration after opening extends shelf life.
• Injection sites (SubQ) — Abdomen or thigh; rotate. Larger volumes may require splitting across multiple sites.
• Inspection — IV solution should be clear to very pale yellow. Discard if cloudy, discolored, or contaminated.

→ Use the Kalios Dosing Calculator for parenteral NAD+

Side Effects & Risks

NAD+ has a generally favorable safety profile with modality-specific nuances.

• IV NAD+ infusion discomfort — Slowing required. Too-fast infusion produces chest tightness, shortness of breath, GI cramping, flushing, nausea. Slow infusion (1–2 mg/min) largely eliminates these symptoms.
• Flushing (niacin) — Nicotinic acid produces prostaglandin D2-mediated flushing; can be severe at 500+ mg. NAM and NR do not flush.
• GI upset (oral NMN/NR) — Occasional nausea or bloating, particularly at higher doses. Usually mild.
• Headache — Occasional with IV infusion, usually mild.
• Liver function changes (IV) — Grant 2019 documented transient shifts in bilirubin, GGT, AST, LD at 8 hours post-infusion. Direction was favorable (decrease in GGT, AST, LD) but requires monitoring in users with liver disease.
• Vivid dreams / sleep changes — Reported with NMN and NR, particularly with evening dosing. Some users benefit; others report insomnia.
• Blood pressure effect (NR) — Modest decrease in systolic BP in the Martens 2018 stage-1 hypertensive subgroup. Anti-hypertensive medication may need adjustment with high-dose NR.
• Methyl-group consumption — NAM is methylated to MeNAM for urinary excretion, consuming methyl donors (SAM, B12, folate). Chronic very high-dose NAM may deplete methyl donor pool; adding methylfolate / methylcobalamin is prudent for chronic high-dose protocols.
• Hepatotoxicity (very high-dose niacin) — Sustained-release niacin >2 g/day has been associated with hepatotoxicity; immediate-release and lower doses are generally safe.
• Cancer caution — Theoretical concern based on sirtuin/NAD+ support of some cancer cell phenotypes. Avoid NAD+ boosting with active malignancy or high cancer risk profile without oncologist consultation.
• Purity and sourcing — Oral NR and NMN vary widely in authenticity; third-party HPLC purity testing has found meaningful percentages of underdosed or adulterated products. Use branded, tested ingredients (Niagen for NR; validated brands for NMN).
• Regulatory NMN question — FDA has stated NMN does not meet the Dietary Supplement definition because it was investigated as a drug. Enforcement has been inconsistent; NMN remains broadly available in the U.S. supplement market as of April 2026.

Supportive Nutrition & Supplements

NAD+ modulation interacts with broader nutritional and lifestyle variables. The following apply to anyone running NAD+ protocols for general health or longevity purposes.

• Methyl donor support — Methylfolate (400–800 mcg), methylcobalamin (1,000 mcg), and TMG (500–1,500 mg) support the NAM methylation / excretion pathway. Particularly important for chronic high-dose NAM or niacin protocols.
• Dietary tryptophan and niacin — Background dietary niacin (turkey, chicken, fish) and tryptophan contribute to baseline NAD+ via de novo synthesis. A low-protein diet undercuts this foundation.
• Caloric restriction / time-restricted eating — CR and TRE activate NAMPT and raise NAD+ endogenously. The best-evidenced behavioral NAD+ lever is a modest caloric deficit and/or 12–16 hour overnight fasting.
• Exercise — Aerobic and resistance exercise elevate NAD+ and activate sirtuins. Highest-leverage lifestyle input for NAD+ biology.
• Sleep (7–9 hours) — Circadian rhythm interacts with NAD+ oscillation; sleep restriction disrupts the NAD+-SIRT1-CLOCK feedback loop.
• Alcohol — Acute alcohol metabolism consumes NAD+ (NADH accumulation). Heavy chronic alcohol is the most common depleter of hepatic NAD+.
• CD38 inhibitors (experimental) — Quercetin, luteolin, and apigenin are flavonoid CD38 inhibitors that may preserve NAD+ by reducing its consumption. Preclinical evidence stronger than clinical.
• Omega-3 (2–3 g EPA/DHA) — Mitochondrial membrane support; complements NAD+ pathway.
• Creatine monohydrate (3–5 g) — ATP buffering; complementary to mitochondrial ATP generation.

What to Expect — Timeline

Experience varies by modality. The following synthesizes RCT data and patient-reported patterns across oral precursors and IV infusion.

• Oral NR / NMN — week 1–2 — Subtle changes. Some users report improved energy within days; others no change. Blood NAD+ rises detectably within days (Airhart 2017 showed doubling by day 8).
• Oral NR / NMN — week 3–6 — Where measurable effects emerge. Martens 2018 BP and arterial stiffness at 6 weeks; Yoshino insulin sensitivity at 10 weeks. Modest, consistent effects.
• Oral NR / NMN — month 2–3 — Plateau. Continued dosing maintains elevated NAD+ without further dramatic subjective change.
• IV NAD+ loading — during infusion — First 30 minutes often unpleasant if rate too fast (chest tightness, GI discomfort); slows with rate adjustment. Many users describe "foggy" or "heavy" in-infusion feeling.
• IV NAD+ loading — after infusion — Subjective clarity or energy commonly reported within 1–3 days post-first infusion. Loading protocols of 5–10 daily infusions build cumulative effect.
• IV NAD+ maintenance — Monthly infusions maintain perceived benefit in users who responded to loading.
• Non-responders — Real. Some users describe no subjective change on oral or IV NAD+. Blood NAD+ rise may still occur; functional endpoints don't always follow.
• Addiction medicine protocols (historical) — Report dramatic improvement in withdrawal symptoms within hours of IV NAD+; evidence is experiential and historical rather than RCT-level.

Bloodwork & Monitoring

NAD+ biomarker tracking is possible but logistically involved. Practical monitoring:

• Whole blood NAD+ metabolome — Specialty labs (Jinfiniti, research protocols) measure blood NAD+ and related metabolites. Baseline before starting; repeat at 6–12 weeks. Not routine clinical lab.
• Baseline CMP — Liver, kidney, glucose. Repeat with chronic use.
• HbA1c + fasting glucose — Baseline; relevant for NMN/NR given the Yoshino muscle insulin sensitivity signal.
• Blood pressure — Baseline and during NR dosing (modest lowering documented).
• Lipid panel — Relevant for niacin (significantly lowers LDL, raises HDL); less for NR/NMN.
• Methylation markers — Homocysteine, B12, folate. Relevant for chronic high-dose NAM users.
• Inflammation markers — hsCRP baseline; NR has modest anti-inflammatory signals.
• Cognitive tracking — If cognitive benefit is the target, validated cognitive batteries at baseline and 8–12 weeks give objective data.
• Body composition / DEXA — For metabolic protocols, DEXA captures fat-mass vs lean-mass changes better than scale weight.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching NAD+ often also look at these:

Next Steps

Key References

1. Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. PMID: 26785480.
2. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PMID: 24786309.
3. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. PMID: 24360282.
4. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, Guarente L, Auwerx J. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154(2):430-441. PMID: 23870130.
5. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596.
6. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478.
7. Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459. PMID: 29211728.
8. Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMID: 31572171.
9. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.e6. PMID: 31390667.
10. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. PMID: 30084900.
11. Vreones M, Mustapic M, Moaddel R, Pucha KA, Lovett J, Seals DR, Kapogiannis D, Martens CR. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023;22(1):e13754. PMID: 36448627.
12. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-1626. PMID: 26488693.
13. Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. PMID: 27304511.
14. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689.
15. Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. 2022;34(3):396-407.e6. PMID: 35537443.
16. Freeberg KA, Craighead DH, Martens CR, You Z, Chonchol M, Seals DR. Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. Front Cardiovasc Med. 2022;9:881703. PMID: 35757350.
17. Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito K. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023;13(1):2786. PMID: 36797283.
18. Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, Bohr VA. NAD⁺ in Aging: Molecular Mechanisms and Translational Implications. Trends Mol Med. 2017;23(10):899-916. PMID: 28899755.